D. E. Shaw & Co., Inc. Tyme Technologies, Inc. Transaction History

D. E. Shaw & Co., Inc.

$98.6 Billion
Q2 2024

Shares

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2022 Aug 15, 2022	SELL	$0.23 - $0.35 $4,320 - $6,574	-18,783 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$0.28 - $0.68 $368 - $894	-1,315 Reduced 6.54%	18,783 $7,000
Q4 2021 Feb 14, 2022	SELL	$0.6 - $1.04 $7,480 - $12,965	-12,467 Reduced 38.28%	20,098 $12,000
Q3 2021 Nov 15, 2021	SELL	$0.99 - $1.38 $32,076 - $44,712	-32,400 Reduced 49.87%	32,565 $34,000
Q2 2021 Aug 16, 2021	BUY	$1.14 - $1.87 $59,059 - $96,879	51,807 Added 393.73%	64,965 $82,000
Q1 2021 May 17, 2021	BUY	$1.34 - $3.53 $17,631 - $46,447	13,158 New	13,158 $23,000
Q3 2020 Nov 16, 2020	SELL	$0.93 - $1.35 $9,735 - $14,131	-10,468 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$0.97 - $1.7 $10,153 - $17,795	10,468 New	10,468 $14,000
Q2 2019 Aug 14, 2019	SELL	$0.96 - $1.89 $53,418 - $105,167	-55,644 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$1.76 - $3.73 $97,933 - $207,552	55,644 New	55,644 $98,000

About TYME TECHNOLOGIES, INC.

Ticker TYME
Exchange NASDAQ
Shares Outstandng 172,207,008
Description
Tyme Technologies, Inc., a biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead drug product is SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, prostate, breast, lung, glioma, ovarian, sarcoma, and colon. The company is also devel...

More about TYME

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.